Ftse Mib
37.242,17
0,50%
DAX
21.911,74
0,68%
S&P 500
6.066,44
0,67%
NASDAQ
19.714,27
0,98%
Bitcoin
98.267,53
0,81%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Keros Therapeutics Inc (KROS) Keros Therapeutics Inc (KROS) Notizie

KROS

Keros Therapeutics (KROS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KROS
DataOraFonteTitoloSimboloCompagnia
30/01/202514:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
30/01/202514:00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceNASDAQ:KROSKeros Therapeutics Inc
24/01/202522:15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:KROSKeros Therapeutics Inc
21/01/202514:00GlobeNewswire Inc.Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
15/01/202512:30GlobeNewswire Inc.Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
12/12/202412:00GlobeNewswire Inc.Keros Therapeutics Announces Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
10/12/202401:30GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
03/12/202413:00GlobeNewswire Inc.Keros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
26/11/202414:00GlobeNewswire Inc.Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
12/11/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
08/11/202422:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/11/202422:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
06/11/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceNASDAQ:KROSKeros Therapeutics Inc
05/11/202415:00GlobeNewswire Inc.Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
16/10/202414:00GlobeNewswire Inc.Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical OfficerNASDAQ:KROSKeros Therapeutics Inc
12/09/202414:00GlobeNewswire Inc.Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
03/09/202414:00GlobeNewswire Inc.Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
07/08/202422:01GlobeNewswire Inc.Keros Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
17/06/202423:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
17/06/202422:01GlobeNewswire Inc.Keros Therapeutics Announces Leadership UpdatesNASDAQ:KROSKeros Therapeutics Inc
17/06/202412:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202414:00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/05/202422:01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202416:00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202414:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202413:00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
05/03/202414:00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202422:01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
29/01/202414:00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KROS

La tua Cronologia

BIT
UCG
Unicredit
BIT
BPE
Bper Banca
BIT
TIT
Telecom Italia
BIT
IVG
Iveco Group NV
BIT
ISP
Intesa Sanpaolo
BIT
BAMI
Banco BPM
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BPSO
Banca Popolare di Sondrio
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
NEXI
Nexi S.p.A
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci